

[Skip to main content](#)

Bontril SR (Phendimetrazine Tartrate Slow Release Capsules)

??? ??????: 30 ?????2/?????? 2017

Palpitation, tachycardia, elevation of blood pressure. **Cardiovascular:**

Overstimulation, restlessness, dizziness, insomnia, tremor, headache; rarely psychotic episodes at recommended doses, agitation, **Central Nervous System:** flushing, sweating, blurring of vision.

Dryness of the mouth, diarrhea, constipation, nausea, stomach pain. **Gastrointestinal:**

Changes in libido, urinary frequency, dysuria. **Genitourinary:**

Drug Abuse And Dependence

Phendimetrazine is a Schedule III controlled substance. **Controlled Substance:**

Phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been **Dependence:** extensively abused, and the possibility of abuse of phendimetrazine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia.